## ALNY: Alnylam Pharmaceuticals, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -8.2% below STRENGTH zone (3.0-6.0%); PEG unavailable fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-11.2% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($380.07)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 7
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Thematics Asset Management Purchases New Shares in Alnylam Pharmaceuticals, Inc. $ALNY**
- Source: MarketBeat | 20251209T140909 | Neutral | Relevance: 99%
-  Thematics Asset Management initiated a new position in Alnylam Pharmaceuticals (NASDAQ:ALNY) during the second quarter, acquiring 6,118 shares valued at approximately $1.995 million. Despite institutional buying, company insiders, including CEO Yvonne Greenstreet and EVP Kevin Fitzgerald, have been selling shares, totaling 60,328 shares worth about $27.3 million in the last 90 days. Analysts currently maintain a "Moderate Buy" consensus rating with an average target price of $482.17, suggesting potential upside from its current trading price near $430.

**2. Is Alnylam Pharmaceuticals a Millionaire Maker?**
- Source: Finviz | 20251207T051222 | Bullish | Relevance: 99%
-  Alnylam Pharmaceuticals, co-founded by MIT professor Phillip Sharp, focuses on RNA interference therapies, a field that won the Nobel Prize in 2006. Since its IPO in 2004, a $10,000 investment would be worth approximately $787,000 today, demonstrating significant growth. The company has several approved products and a promising pipeline, with its Amvuttra drug becoming a potential blockbuster due to its new indication.

**3. Mirabella Financial Services LLP Decreases Stake in Alnylam Pharmaceuticals, Inc. $ALNY**
- Source: MarketBeat | 20251207T051222 | Neutral | Relevance: 99%
-  Mirabella Financial Services LLP significantly reduced its stake in Alnylam Pharmaceuticals, Inc. by 74.7% in Q2, selling 8,767 shares and retaining 2,970 shares valued at approximately $973,000. Company insiders have also sold a substantial number of shares recently, totaling $35.7 million in the past 90 days. Despite these sales, analysts maintain a "Moderate Buy" consensus rating with a target price of $482.17 for ALNY.

**4. Winslow Capital Management LLC Has $383.95 Million Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY**
- Source: MarketBeat | 20251208T130938 | Somewhat-Bullish | Relevance: 98%
-  Winslow Capital Management LLC slightly reduced its stake in Alnylam Pharmaceuticals ($ALNY) by 0.8% to 1,177,439 shares, valued at $383.95 million, making it their 26th largest holding. Despite insider selling totaling approximately $35.7 million over the last three months, Wall Street maintains a "Moderate Buy" consensus with an average target price of $482.17, supported by mostly positive analyst ratings and recent price target increases. The biopharmaceutical company's stock has seen significant institutional investment, with shareholders owning 92.97% of the company, and its share price has soared 65% recently.

**5. Will Board Overhaul And CEO Stock Moves Reshape Alnylam Pharmaceuticals' (ALNY) RNAi Investment Narrative**
- Source: Simply Wall Street | 20251207T051222 | Somewhat-Bullish | Relevance: 97%
- Alnylam Pharmaceuticals has recently seen a board overhaul, with new independent director Stuart Arbuckle set to join and CEO Yvonne Greenstreet exercising significant stock options. This leadership shift is expected to influence the company's RNAi investment narrative, particularly focusing on commercialization and the TTR franchise, with projections of substantial revenue and earnings growth by 2028. Investors are encouraged to consider the company's strong TTR momentum against potential pricing and payer pressures.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-11 | Wells Fargo | $479 | $395 | +21% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-11 | Wells Fargo | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 7 ($0.03M) |
| Sells | 9 ($1.84M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 64.6% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- FMR, LLC: 12.7% (+6.1%)
- Capital World Invest: 12.4% (-2.2%)
- Vanguard Group Inc: 10.3% (+2.0%)
- Blackrock Inc.: 7.5% (-0.8%)
- JPMORGAN CHASE & CO: 6.9% (+340.7%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-11.2% 5d) with bearish MACD, trend may be turning.
2. Near-term weakness: 8.9% below SMA50 despite long-term uptrend.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

Forward P/E 39.1x attractive for 114% earnings growth. Quality metrics strong (ROE 33%). Balance sheet: strong liquidity (2.5x). Revenue growth strong at 43% YoY. Analyst sentiment positive (1 raises, avg +21%). Insider selling cluster ($1.8M in 90 days), potential headwind. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $54.9B |
| Beta | 0.30 |
| 52W Range | $205.87 - $495.55 |
| Short Interest | 4.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | -0.49 |
| Forward P/E | 39.1 |
| Current P/E | 83.7 |
| YoY Growth | 113.8% |
| EPS Direction | RISING |

### Technicals

MRS_10 deteriorating from 3.0% to -8.2% (-11.2% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 11.2pp (needs >3.0% for momentum thesis). Underperforming sector by 3.7pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.16x) but short-term weakness (below SMA20). MACD histogram bearish (-2.13), momentum weakening.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -8.19% (CS: 1) | Weak |
| RSI_14 | 35.6 | Neutral |
| MACD Histogram | -2.13 | Bearish |
| vs SMA20 | 0.923x | Below |
| vs SMA50 | 0.911x | Below |
| vs SMA200 | 1.155x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $415.21
- **Stop Loss:** $380.07 (8.5% risk)
- **Target:** $450.35 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 8
- **Position Value:** $3,321.68
- **Portfolio %:** 3.32%
- **Risk Dollars:** $300.00
- **Risk Per Trade:** 0.30%
- **Modifiers:** L1 100% | L2 25% | Combined 0.30x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TOXIC (Zone G) | 0.25x |

*NORMAL regime with moderate risk appetite. VIX remains in the mid-range, breadth is moderate, and yield curve is flat but not invertedâ€”indicating standard late-cycle conditions. Upbeat earnings and positive tech momentum are offset by cautious guidance in consumer sectors, suggesting selective positioning is favored.*

### Earnings

**Next:** 2026-02-12 (Est: $1.73)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.75 | $2.90 | +66.1% |
| 2025Q2 | $0.15 | $0.32 | +119.6% |
| 2025Q1 | $-0.37 | $-0.01 | +97.3% |
| 2024Q4 | $-0.14 | $0.06 | +142.5% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*